Table 1 Study and population characteristics for included studies
First author | Year | Study design | Sample size | Stage | Median/mean age (range) | Median follow-up (months) | Treatment type | Fraction dose (GyE) | Total dose (GyE) | EQD2 | PS | Medically inoperable |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nakayama | 2011 | R | 35 | II-III | 70 (47-85) | 16.9 (NR) | PBT | 2-3.3 | 72.6-83.6 | 67.1-91.3 | 0-2 | 88.6% |
Oshiro | 2012 | R | 57 | III | 72 (42-85) | 16.2 (NR) | PBT | 2-6.6 | 50-84.5 | NC | 0-2 | NR |
Iwata | 2013 | R | 70 | II | 75 (57-92) | 44 (4-103) | PBT or CIRT | 2.7-13.2 | 52.8-80 | 77.7-102.1 | 0-2 | 57.1% |
Oshiro | 2014 | II | 15 | III | 60 (40-68) | 21.7 (NR) | PBT+CC | 2 | 74 | 74 | 0-1 | NR |
Hoppe | 2015 | II | 14 | III | 65 (48-82) | 30 (NR) | PBT+CC | 2 | 12-80 | 12-80 | 0-1 | 100% |
Nguyen | 2015 | P | 134 | II-III | 69 (28-95) | 55.2 (18-80.4) | PBT+CC | 2 | 60-74.1 | 60-74.1 | NR | NR |
Hatayama | 2015 | R | 27 | III | 72 (57-91) | 15.4 (7.8-36.9) | PBT | 2-3.2 | 66-86.4 | NC | 0-1 | NR |
Harada | 2016 | I | 9 | III | 72 (56-74) | 43 (NR) | PBT+CC | 2 | 60-74 | 60-74 | 0-1 | 100% |
Chang | 2017 | II | 64 | III | 70 (37-78) | 27.3 (2.7-111.5) | PBT+CC | 2 | 74 | 74 | NR | NR |
Shirai | 2017 | R | 23 | II-III | 78 (53-91) | 25 (4-54) | CIRT | 4-15 | 52.8-70.4 | 74.7-125.0 | 0-2 | 52.2% |
Saitoh | 2018 | I | 6 | III | 77 (64-80) | 26 (4-43) | CIRT | 4 | 64 | 74.7 | 0-1 | 100% |
Hayashi | 2018 | R | 141 | II-III | 75 (40-88) | 29.3 (1.6-207.7) | CIRT | NR | 54-76 | NC | 0-2 | 78.7% |
Elhammali | 2019 | R | 51 | II-III | 70 (43-83) | 23.0 (0.9-60.1) | PBT+CC | NR | 59.4-78.0 | NC | NR | NR |
Iwata | 2020 | II | 47 | III | 65 (31-74) | 37 (4-84) | PBT+CC | 2 | 70 | 70 | 0-1 | 100% |
Anzai | 2020 | R | 65 | III | 73 (40-88) | 27.6 (1.6-207.7) | CIRT | 4-4.75 | 64-76 | 74.7-93.4 | 0-2 | 83% |
Kim | 2021 | R | 25 | III | 62 (56-75) | 21.7 (16.8-26.8) | PBT+CC | 2-2.2 | 59.4-74 | 60-74 | 0-2 | NR |
Ohnishi | 2021 | R | 45 | III | 62 (39-79) | 42.1 (6.4-127.0) | PBT+CC | 2 | 74 | 74 | 0-1 | NR |
Contreras | 2021 | I | 20 | II-III | 66 (52-89) | 20.3 (1-38) | PBT+CC | 3.5-4 | 52.5-60 | 59.1-70 | 0-2 | NR |
Hoppe | 2022 | I/II | 28 | II-III | 70 (50-86) | 31 (1-82) | PBT+CC | 2.5-4 | 60 | 62.5-70.0 | 0-1 | NR |